New clinical findings, legal settlements and expanding use cases are shaping the GLP-1 landscape across oncology, pediatrics and addiction care. Here are nine GLP-1 updates to know.
GLP-1s
Pharmacies have been seeing compelling interest in Medicare’s GLP-1 Bridge program since its July launch, NPR first reported. The demonstration, designed to give eligible Medicare Part D beneficiaries access to certain GLP-1s at a fixed monthly cost, will run through…
Santa Fe, N.M.-based Quel Health launched a telehealth platform focused on using GLP-1 receptor agonists in addiction care. The platform is available in 41 states and the District of Columbia, with national coverage planned by year-end, according to a Sept.…
Novo Nordisk has secured a permanent injunction restricting LifeRxMD from making certain claims involving Ozempic, Wegovy and Rybelsus in its marketing of compounded drugs. The injunction was entered as part of a confidential settlement between Novo Nordisk and LifeRxMD, according…
Two out of every 5 young children who took Novo Nordisk’s weight-loss drug Wegovy in a clinical trial lost enough weight to no longer be classified as having obesity, the drugmaker announced Sept. 7. When combined with diet and exercise,…
Advertisement
The FDA is warning patients and healthcare professionals about safety and quality concerns involving compounded GLP-1 drugs and unapproved weight-loss drugs as adverse event reports involving compounded semaglutide and tirzepatide surpass 1,700. Here are four things to know:
GLP-1 use among young children with obesity remains rare but increased rapidly from 2019 to 2026, according to a study published Sept. 4 in Pediatrics. Here are five things to know:
GLP-1 prescribing increased faster among adults with serious mental illness than among those without serious mental illness from 2018 to 2024, according to a Sept. 2 study published in JAMA Psychiatry. Here are five things to know:
More than 450 employees at The Cigna Group have signed a petition challenging the company’s decision to end GLP-1 weight-loss coverage for its workforce. Cigna stopped covering GLP-1s for weight loss through its employee health plan July 1. The company…
More than a dozen experimental obesity drugs are working their way through clinical trials, and the last year has reshuffled the leaderboard: some candidates have advanced into pivotal phase 3 studies, others have won approval overseas and at least one…